ARTICLE | Clinical News
TT-223: Phase II data
February 1, 2010 8:00 AM UTC
Data from a double-blind, dose-ranging, U.S. Phase II trial in about 80 patients on background metformin or thiazolidinedione therapy showed that 3 mg once-daily subcutaneous TT-223 met the secondary ...